Details of the Drug Combination

General Information of Drug Combination (ID: DCUVUW9)

Drug Combination Name
Camptothecin Ruxolitinib
Indication
Disease Entry Status REF
Hodgkin lymphoma Investigative [1]
Component Drugs Camptothecin   DM6CHNJ Ruxolitinib   DM7Q98D
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: L-1236
Zero Interaction Potency (ZIP) Score: 0.55
Bliss Independence Score: 0.05
Loewe Additivity Score: 1.58
LHighest Single Agent (HSA) Score: 3.55

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Camptothecin
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
Camptothecin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Camptothecin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [17]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [18]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [19]
------------------------------------------------------------------------------------
Camptothecin Interacts with 171 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Expression [20]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Decreases Expression [9]
Frataxin, mitochondrial (FXN) OTE9U09A FRDA_HUMAN Increases Expression [21]
Serine/threonine-protein kinase Chk2 (CHEK2) OT8ZPCNS CHK2_HUMAN Increases Expression [14]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Expression [22]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Expression [22]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Decreases Expression [22]
Transcription factor SOX-12 (SOX12) OT93P8C9 SOX12_HUMAN Increases Methylation [10]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases Expression [10]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [10]
Retinoic acid receptor alpha (RARA) OT192V9V RARA_HUMAN Increases Methylation [10]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Methylation [10]
Adenomatous polyposis coli protein (APC) OTKV0TIK APC_HUMAN Increases Methylation [10]
Transcription factor SOX-11 (SOX11) OT4LG7LA SOX11_HUMAN Increases Methylation [10]
Activin receptor type-1B (ACVR1B) OT778HIQ ACV1B_HUMAN Increases Methylation [10]
Transcription factor SOX-3 (SOX3) OT1CRCOB SOX3_HUMAN Increases Methylation [10]
Transcription factor SOX-8 (SOX8) OTEJXYZM SOX8_HUMAN Increases Methylation [10]
Caveolin-1 (CAV1) OTEZUR1L CAV1_HUMAN Decreases Methylation [10]
Transcription factor SOX-4 (SOX4) OTSS40SS SOX4_HUMAN Increases Methylation [10]
Centrosomal protein of 85 kDa-like (CEP85L) OTSHJFOT CE85L_HUMAN Increases Methylation [10]
Centrosome-associated protein ALMS1 (ALMS1) OTW66JKS ALMS1_HUMAN Decreases Methylation [10]
Solute carrier family 2, facilitated glucose transporter member 12 (SLC2A12) OT0EDNV9 GTR12_HUMAN Increases Methylation [10]
AMSH-like protease (STAMBPL1) OTI4CYTF STALP_HUMAN Increases Methylation [10]
Frizzled-8 (FZD8) OTZ9IRFL FZD8_HUMAN Decreases Methylation [10]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Increases Methylation [10]
Frizzled-1 (FZD1) OTZATHVS FZD1_HUMAN Decreases Methylation [10]
Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 1 (AGAP1) OTVX8835 AGAP1_HUMAN Increases Methylation [10]
Transcription factor E2F8 (E2F8) OTQKZGFP E2F8_HUMAN Increases Expression [13]
Transmembrane protein 250 (TMEM250) OTLJ4G5G TM250_HUMAN Increases Expression [13]
Agrin (AGRN) OTWJENAZ AGRIN_HUMAN Increases Expression [23]
Etoposide-induced protein 2.4 homolog (EI24) OTD4NOYS EI24_HUMAN Increases Expression [23]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Increases Expression [24]
Tax1-binding protein 3 (TAX1BP3) OTQ6IB4T TX1B3_HUMAN Increases Expression [23]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [25]
SLIT-ROBO Rho GTPase-activating protein 3 (SRGAP3) OT9ZS72C SRGP3_HUMAN Decreases Expression [13]
Histone-lysine N-methyltransferase SUV39H1 (SUV39H1) OTDTF5BU SUV91_HUMAN Increases Expression [13]
Cytoplasmic protein NCK2 (NCK2) OTUYPF55 NCK2_HUMAN Decreases Expression [23]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Decreases Expression [23]
A-kinase anchor protein 8 (AKAP8) OTK3EQAI AKAP8_HUMAN Increases Expression [13]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G) OT8V1J4M GA45G_HUMAN Increases Expression [11]
Ubiquitin-like modifier-activating enzyme ATG7 (ATG7) OTVT4YA1 ATG7_HUMAN Increases Expression [26]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Increases Expression [26]
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Binding [27]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Phosphorylation [26]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [28]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Increases Phosphorylation [28]
DNA excision repair protein ERCC-1 (ERCC1) OTNPYQHI ERCC1_HUMAN Decreases Expression [11]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Decreases Expression [29]
Transcription factor Sp1 (SP1) OTISPT4X SP1_HUMAN Increases Expression [24]
Interleukin-6 receptor subunit alpha (IL6R) OTCQL07Z IL6RA_HUMAN Decreases Expression [12]
Galectin-1 (LGALS1) OT8LDFWR LEG1_HUMAN Decreases Expression [30]
Annexin A4 (ANXA4) OTUCRYXL ANXA4_HUMAN Increases Expression [23]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [31]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [12]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [25]
Microtubule-associated protein tau (MAPT) OTMTP2Z7 TAU_HUMAN Decreases Expression [32]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Decreases Expression [12]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [12]
C-C motif chemokine 5 (CCL5) OTSCA5CK CCL5_HUMAN Decreases Expression [12]
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) OTPWI88U CEAM1_HUMAN Increases Expression [23]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Decreases Expression [33]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [34]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Decreases Expression [35]
Syndecan-1 (SDC1) OTWKRVZC SDC1_HUMAN Increases Expression [23]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [26]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [36]
NADPH:adrenodoxin oxidoreductase, mitochondrial (FDXR) OTPDCK1F ADRO_HUMAN Increases Expression [23]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Decreases Expression [11]
G1/S-specific cyclin-E1 (CCNE1) OTLD7UID CCNE1_HUMAN Increases Expression [24]
Retinoblastoma-like protein 1 (RBL1) OTDEBFYC RBL1_HUMAN Decreases Expression [28]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Increases Phosphorylation [24]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Decreases Expression [36]
Coilin (COIL) OTP4I4DL COIL_HUMAN Increases Expression [13]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [37]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Increases Expression [23]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Expression [38]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [39]
Caspase-2 (CASP2) OTUDYSPP CASP2_HUMAN Increases Expression [40]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Phosphorylation [41]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Increases Phosphorylation [28]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3) OTI2OREX MP2K3_HUMAN Increases Expression [23]
Double-strand break repair protein MRE11 (MRE11) OTGU8TZM MRE11_HUMAN Decreases Expression [11]
Breast cancer type 2 susceptibility protein (BRCA2) OTF1XSV1 BRCA2_HUMAN Decreases Expression [42]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Decreases Expression [36]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Decreases Expression [36]
Hepcidin (HAMP) OT607RBL HEPC_HUMAN Decreases Expression [43]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [44]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [45]
Transcription factor Sp3 (SP3) OTYDQZ1T SP3_HUMAN Increases Activity [46]
Antigen peptide transporter 1 (TAP1) OTJL27PW TAP1_HUMAN Increases Expression [23]
CCAAT/enhancer-binding protein zeta (CEBPZ) OT11BATG CEBPZ_HUMAN Decreases Expression [23]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Decreases Expression [42]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Decreases Expression [36]
Histone acetyltransferase p300 (EP300) OTL8QJDX EP300_HUMAN Decreases Expression [42]
Unconventional myosin-Ie (MYO1E) OTM9YSIZ MYO1E_HUMAN Decreases Expression [13]
Vesicle transport protein SEC20 (BNIP1) OT7USYCY SEC20_HUMAN Increases Expression [13]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Increases Expression [41]
Transcription intermediary factor 1-beta (TRIM28) OTE38OBF TIF1B_HUMAN Increases Expression [47]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Decreases Expression [11]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Degradation [48]
Beclin-1 (BECN1) OT4X293M BECN1_HUMAN Increases Expression [26]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Decreases Expression [36]
Cyclin-dependent kinase 5 activator 1 (CDK5R1) OTJELWK0 CD5R1_HUMAN Increases Expression [13]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Activity [24]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Decreases Expression [36]
Quinone oxidoreductase PIG3 (TP53I3) OTSCM68G QORX_HUMAN Increases Expression [23]
EPM2A-interacting protein 1 (EPM2AIP1) OT21ALNF EPMIP_HUMAN Increases Expression [23]
tRNA-uridine aminocarboxypropyltransferase 1 (DTWD1) OT95QT6P DTWD1_HUMAN Increases Expression [13]
TBC1 domain family member 16 (TBC1D16) OTPR3C6A TBC16_HUMAN Decreases Expression [13]
Protein Jumonji (JARID2) OT14UM8H JARD2_HUMAN Decreases Expression [13]
DNA repair protein RAD50 (RAD50) OTYMU9G1 RAD50_HUMAN Decreases Expression [11]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Decreases Expression [25]
Small glutamine-rich tetratricopeptide repeat-containing protein beta (SGTB) OTYZL88Z SGTB_HUMAN Decreases Expression [13]
Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) OTQR6ENW M3K5_HUMAN Decreases Expression [23]
Tumor protein 63 (TP63) OT0WOOKQ P63_HUMAN Decreases Expression [33]
Serine/threonine-protein kinase PLK3 (PLK3) OT19CT2Z PLK3_HUMAN Increases Expression [23]
Sphingomyelin phosphodiesterase 3 (SMPD3) OTHQBETH NSMA2_HUMAN Increases Expression [49]
PH and SEC7 domain-containing protein 3 (PSD3) OTTN9B9O PSD3_HUMAN Decreases Expression [13]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Phosphorylation [26]
Kelch-like protein 42 (KLHL42) OTK6WARI KLH42_HUMAN Increases Expression [13]
Calcium-binding protein 39 (CAB39) OT2CL9ST CAB39_HUMAN Decreases Expression [23]
RWD domain-containing protein 3 (RWDD3) OTE76DY5 RWDD3_HUMAN Increases Expression [13]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Response To Substance [50]
Integrin-binding sialoprotein (IBSP) OT29944Y SIAL_HUMAN Decreases Response To Substance [14]
E3 ubiquitin-protein ligase RNF31 (RNF31) OT4BZONL RNF31_HUMAN Decreases Response To Substance [14]
Survival motor neuron protein (SMN2) OT54RLO1 SMN_HUMAN Increases Response To Substance [39]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Decreases Response To Substance [14]
Agouti-related protein (AGRP) OT7XRHWU AGRP_HUMAN Decreases Response To Substance [14]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform (PPP2R5E) OT8GPFT5 2A5E_HUMAN Decreases Response To Substance [51]
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (PPP2R2A) OT9297OG 2ABA_HUMAN Decreases Response To Substance [51]
Cytochrome P450 26B1 (CYP26B1) OT92XA92 CP26B_HUMAN Decreases Response To Substance [14]
Tumor susceptibility gene 101 protein (TSG101) OT97UIXC TS101_HUMAN Decreases Response To Substance [14]
TNF receptor-associated factor 6 (TRAF6) OTA5GO5K TRAF6_HUMAN Decreases Response To Substance [14]
Retinoblastoma-like protein 2 (RBL2) OTBQSOE6 RBL2_HUMAN Decreases Response To Substance [28]
Protein sel-1 homolog 1 (SEL1L) OTC0FB7T SE1L1_HUMAN Decreases Response To Substance [14]
Protein prenyltransferase alpha subunit repeat-containing protein 1 (PTAR1) OTCT7YPX PTAR1_HUMAN Decreases Response To Substance [14]
Lipid scramblase CLPTM1L (CLPTM1L) OTDJWQXI CLP1L_HUMAN Increases Response To Substance [52]
Caspase-10 (CASP10) OTE6J88E CASPA_HUMAN Decreases Response To Substance [14]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform (PPP2R5C) OTF7CGO2 2A5G_HUMAN Increases Response To Substance [51]
DNA repair endonuclease XPF (ERCC4) OTFIOPG1 XPF_HUMAN Decreases Response To Substance [34]
Receptor-type tyrosine-protein phosphatase O (PTPRO) OTFLKWOY PTPRO_HUMAN Decreases Response To Substance [14]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [53]
Serine/threonine-protein kinase ATR (ATR) OTH0OP1J ATR_HUMAN Decreases Response To Substance [14]
Cone-rod homeobox protein (CRX) OTH435SV CRX_HUMAN Decreases Response To Substance [14]
Disintegrin and metalloproteinase domain-containing protein 19 (ADAM19) OTH88TXU ADA19_HUMAN Decreases Response To Substance [14]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Decreases Response To Substance [25]
Leucine-rich repeat and calponin homology domain-containing protein 4 (LRCH4) OTJFA4AV LRCH4_HUMAN Decreases Response To Substance [14]
Diacylglycerol kinase zeta (DGKZ) OTJQTZUX DGKZ_HUMAN Decreases Response To Substance [14]
Homeobox protein Hox-A1 (HOXA1) OTMSOJ7D HXA1_HUMAN Decreases Response To Substance [14]
Myotubularin-related protein 2 (MTMR2) OTNCYGBP MTMR2_HUMAN Decreases Response To Substance [14]
Neural cell adhesion molecule 1 (NCAM1) OTNUHAC1 NCAM1_HUMAN Decreases Response To Substance [14]
Olfactory receptor 7C2 (OR7C2) OTO7MWWV OR7C2_HUMAN Decreases Response To Substance [14]
A-kinase anchor protein 13 (AKAP13) OTOZAR14 AKP13_HUMAN Decreases Response To Substance [14]
TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 (TAB2) OTPZK76F TAB2_HUMAN Decreases Response To Substance [14]
ARF GTPase-activating protein GIT2 (GIT2) OTQ2EQJ1 GIT2_HUMAN Decreases Response To Substance [14]
Phospholipid hydroperoxide glutathione peroxidase GPX4 (GPX4) OTRAFFX2 GPX4_HUMAN Decreases Response To Substance [14]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Response To Substance [14]
MTRF1L release factor glutamine methyltransferase (HEMK1) OTSHNL5K HEMK1_HUMAN Decreases Response To Substance [14]
Protein phosphatase 1 regulatory subunit 1B (PPP1R1B) OTSIJMQ9 PPR1B_HUMAN Decreases Response To Substance [54]
Serine/threonine/tyrosine-interacting-like protein 1 (STYXL1) OTSPVITK STYL1_HUMAN Decreases Response To Substance [14]
Apoptosis-inducing factor 3 (AIFM3) OTSWKCAO AIFM3_HUMAN Decreases Response To Substance [14]
Serine/threonine-protein kinase Chk1 (CHEK1) OTTTI622 CHK1_HUMAN Decreases Response To Substance [14]
DNA repair protein RAD51 homolog 3 (RAD51C) OTUD6SY5 RA51C_HUMAN Increases Response To Substance [55]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Increases Response To Substance [56]
Mitogen-activated protein kinase kinase kinase 7 (MAP3K7) OTUXEASC M3K7_HUMAN Decreases Response To Substance [14]
Olfactory receptor 1A2 (OR1A2) OTVRC7A5 OR1A2_HUMAN Decreases Response To Substance [14]
Potassium channel subfamily K member 2 (KCNK2) OTWBT8MG KCNK2_HUMAN Decreases Response To Substance [14]
Artemin (ARTN) OTWIWGL6 ARTN_HUMAN Decreases Response To Substance [14]
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (PPP2R1A) OTYA3GB4 2AAA_HUMAN Decreases Response To Substance [14]
Protein phosphatase 1 regulatory inhibitor subunit 16B (PPP1R16B) OTZJFX5C PP16B_HUMAN Decreases Response To Substance [14]
Ataxin-3-like protein (ATXN3L) OTZV3BG4 ATX3L_HUMAN Decreases Response To Substance [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 171 DOT(s)
Indication(s) of Ruxolitinib
Disease Entry ICD 11 Status REF
Essential thrombocythemia 3B63.1Z Approved [3]
High-risk myelofibrosis 2A20.2 Approved [4]
Myelofibrosis 2A22 Approved [5]
Myeloproliferative neoplasm 2A20 Approved [6]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [7]
Pancreatic cancer 2C10 Phase 3 [4]
Atopic dermatitis EA80 Phase 1/2 [8]
Vitiligo ED63.0 Phase 1/2 [8]
Ruxolitinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Modulator [57]
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Modulator [57]
Urokinase plasminogen activator surface receptor (PLAUR) TTPRL03 UPAR_HUMAN Inhibitor [58]
HUMAN janus kinase 1 (JAK-1) TTWKB01 JAK1_HUMAN Inhibitor [59]
HUMAN janus kinase 2 (JAK-2) TT0F5HE JAK2_HUMAN Inhibitor [59]
------------------------------------------------------------------------------------
Ruxolitinib Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Increases ADR [60]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Ruxolitinib FDA Label
7 Incyte begins Phase III trial of ruxolitinib to treat Covid-19. 20.April.2020.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
10 Reduced camptothecin sensitivity of estrogen receptor-positive human breast cancer cells following exposure to di(2-ethylhexyl)phthalate (DEHP) is associated with DNA methylation changes. Environ Toxicol. 2019 Apr;34(4):401-414.
11 Myristicin from nutmeg induces apoptosis via the mitochondrial pathway and down regulates genes of the DNA damage response pathways in human leukaemia K562 cells. Chem Biol Interact. 2014 Jul 25;218:1-9. doi: 10.1016/j.cbi.2014.04.014. Epub 2014 Apr 29.
12 Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
13 Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
14 ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
15 Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol Rep. 2005 Nov;14(5):1311-6.
16 PARP1 and XRCC1 exhibit a reciprocal relationship in genotoxic stress response. Cell Biol Toxicol. 2023 Feb;39(1):345-364. doi: 10.1007/s10565-022-09739-9. Epub 2022 Jul 1.
17 Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
18 The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 Jan;24(1):146-9.
19 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
20 GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells. Cancer Lett. 2004 Dec 8;216(1):89-102.
21 Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS One. 2013;8(2):e55940.
22 Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol. 2018 Apr;92(4):1435-1451.
23 Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
24 Camptothecin induces c-Myc- and Sp1-mediated hTERT expression in LNCaP cells: Involvement of reactive oxygen species and PI3K/Akt. Food Chem Toxicol. 2019 May;127:53-60. doi: 10.1016/j.fct.2019.03.001. Epub 2019 Mar 6.
25 SIRT1 inhibition restores apoptotic sensitivity in p53-mutated human keratinocytes. Toxicol Appl Pharmacol. 2014 Jun 15;277(3):288-97. doi: 10.1016/j.taap.2014.04.001. Epub 2014 Apr 12.
26 Camptothecin enhances c-Myc-mediated endoplasmic reticulum stress and leads to autophagy by activating Ca(2+)-mediated AMPK. Food Chem Toxicol. 2018 Nov;121:648-656. doi: 10.1016/j.fct.2018.09.057. Epub 2018 Sep 25.
27 Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem. 2007 May-Jun;18(3):702-16. doi: 10.1021/bc0602735. Epub 2007 Mar 23.
28 pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin Cancer Res. 2004 Dec 1;10(23):8085-93. doi: 10.1158/1078-0432.CCR-04-0996.
29 The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells. Biochim Biophys Acta. 2006 Oct;1763(10):1125-34. doi: 10.1016/j.bbamcr.2006.08.001. Epub 2006 Aug 5.
30 Camptothecin-induced cell proliferation inhibition and apoptosis enhanced by DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine. Biol Pharm Bull. 2009 Jun;32(6):1105-8. doi: 10.1248/bpb.32.1105.
31 Camptothecin and Zeocin can increase p53 levels during all cell cycle stages. Biochem Biophys Res Commun. 2001 Dec 21;289(5):998-1009. doi: 10.1006/bbrc.2001.6073.
32 Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
33 p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells. Biochem Pharmacol. 2013 Apr 1;85(7):999-1006. doi: 10.1016/j.bcp.2013.01.019. Epub 2013 Jan 29.
34 Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res. 2011 May;39(9):3607-20. doi: 10.1093/nar/gkq1304. Epub 2011 Jan 11.
35 Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells. Mol Pharmacol. 2008 Aug;74(2):517-26. doi: 10.1124/mol.107.043620. Epub 2008 May 20.
36 Effects of folic acid on the antiproliferative efficiency of doxorubicin, camptothecin and methyl methanesulfonate in MCF-7 cells by mRNA endpoints. Saudi J Biol Sci. 2018 Dec;25(8):1568-1576. doi: 10.1016/j.sjbs.2016.02.005. Epub 2016 Feb 10.
37 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
38 Tetrandrine and cepharanthine induce apoptosis through caspase cascade regulation, cell cycle arrest, MAPK activation and PI3K/Akt/mTOR signal modification in glucocorticoid resistant human leukemia Jurkat T cells. Chem Biol Interact. 2019 Sep 1;310:108726. doi: 10.1016/j.cbi.2019.108726. Epub 2019 Jun 28.
39 Increased susceptibility of spinal muscular atrophy fibroblasts to camptothecin-induced cell death. Mol Genet Metab. 2005 May;85(1):38-45. doi: 10.1016/j.ymgme.2004.12.015. Epub 2005 Feb 16.
40 Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res. 2004 Jan;2(1):53-61.
41 Camptothecin induces mitotic arrest through Mad2-Cdc20 complex by activating the JNK-mediated Sp1 pathway. Food Chem Toxicol. 2019 May;127:143-155. doi: 10.1016/j.fct.2019.03.026. Epub 2019 Mar 15.
42 Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells. Prostate. 1999 Jun 15;40(1):37-49. doi: 10.1002/(sici)1097-0045(19990615)40:1<37::aid-pros5>3.0.co;2-p.
43 A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol. 2015 May;43(5):404-413.e5. doi: 10.1016/j.exphem.2015.01.005. Epub 2015 Jan 26.
44 Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines. Chem Biol Interact. 2009 Oct 7;181(2):185-92. doi: 10.1016/j.cbi.2009.05.013. Epub 2009 May 27.
45 Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry. 2007 Jul 3;46(26):7765-80. doi: 10.1021/bi700425y. Epub 2007 Jun 8.
46 Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol. 2001 Mar;49(3):345-54.
47 Different ATM Signaling in Response to Chromium(VI) Metabolism via Ascorbate and Nonascorbate Reduction: Implications for in Vitro Models and Toxicogenomics. Environ Health Perspect. 2016 Jan;124(1):61-6. doi: 10.1289/ehp.1409434. Epub 2015 May 15.
48 The autophagy-senescence connection in chemotherapy: must tumor cells (self) eat before they sleep?. J Pharmacol Exp Ther. 2012 Dec;343(3):763-78. doi: 10.1124/jpet.112.197590. Epub 2012 Aug 27.
49 Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim Biophys Acta. 2009 Nov-Dec;1789(11-12):681-90. doi: 10.1016/j.bbagrm.2009.08.006. Epub 2009 Aug 19.
50 A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Lett. 2006 Jan 8;231(1):74-86. doi: 10.1016/j.canlet.2005.01.017.
51 PP2A-B56? complex is involved in dephosphorylation of -H2AX in the repair process of CPT-induced DNA double-strand breaks. Toxicology. 2015 May 4;331:57-65. doi: 10.1016/j.tox.2015.03.007. Epub 2015 Mar 12.
52 Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. PLoS One. 2012;7(6):e36116. doi: 10.1371/journal.pone.0036116. Epub 2012 Jun 4.
53 [Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype]. Zhonghua Zhong Liu Za Zhi. 2000 Jul;22(4):273-5.
54 Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res. 2005 Aug 1;65(15):6583-92. doi: 10.1158/0008-5472.CAN-05-1433.
55 Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010 May;42(5):406-9. doi: 10.1038/ng.570. Epub 2010 Apr 18.
56 The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migration. Mol Biol Cell. 2011 Sep;22(17):3032-40. doi: 10.1091/mbc.E11-04-0280. Epub 2011 Jul 7.
57 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
58 Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69.
59 The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
60 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.